BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/27/2026 8:35:13 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-09-22 03:13 |
|
Peer-Review Started |
|
2025-09-22 03:13 |
|
First Decision by Editorial Office Director |
|
2025-11-04 09:47 |
|
Return for Revision |
|
2025-11-04 09:47 |
|
Revised |
|
2025-11-26 09:05 |
|
Publication Fee Transferred |
|
2025-11-30 13:26 |
|
Second Decision by Editor |
|
2026-01-12 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-12 10:53 |
|
Articles in Press |
|
2026-01-12 10:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-10 08:12 |
|
Publish the Manuscript Online |
|
2026-02-27 08:35 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fen-Qi Du, Jia-Lu Liu, Liu-Dan Mai, Xin-Hao Han, Wen-Jie Song, Da Yang, Qiu-Ju Zhang, Rui Zhang, Yan-Long Liu and Jin-Xue Tong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Heilongjiang Provincial Natural Science Foundation of China |
PL2024H173 |
| Nn10 Project of Harbin Medical University Cancer Hospital |
no.04000079 |
|
| Corresponding Author |
Jin-Xue Tong, Professor, Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, Heilongjiang Province, China. 601705@hrbmu.edu.cn |
| Key Words |
Colorectal cancer; Perioperative carcinoembryonic antigen; Prognostic marker; Recurrence; Metastasis; Adjuvant chemotherapy |
| Core Tip |
Perioperative carcinoembryonic antigen (CEA) is an important prognostic predictor and stratification marker, and it is reasonable to apply perioperative CEA to guide postoperative follow-up of stage II and III colorectal cancer (CRC) patients. The nomogram model based on perioperative CEA can well predict the 3-year, 5-year, and 7-year overall survival and disease-free survival of stage II and III CRC patients. Perioperative CEA can be used to assess recurrence or metastasis features of stage II and III CRC patients. Perioperative CEA, especially postoperative CEA, has the potential to guide adjuvant chemotherapy in stage II and III CRC patients, which is worthy of further study. |
| Publish Date |
2026-02-27 08:35 |
| Citation |
Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; 32(9): 114200 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i9/114200.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i9.114200 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
